Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Questiomycin B. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Questiomycin B SCHEMBL27340296 | 1.00 | ALOX15 (0.71) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL11456566 | 0.98 | ALOX15 (0.68) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL27884541 | 0.91 | ALOX15 (0.71) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL905794 | 0.90 | ALOX15 (0.79) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL28486327 | 0.88 | TSHR (0.68) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL28493249 | 0.88 | TSHR (0.68) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL11337786 | 0.88 | ALOX15 (0.75) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| SCHEMBL18612812 | 0.87 | ALOX15 (0.94) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL28106010 | 0.87 | ALOX15 (0.94) | ALOX15TSHRALDH1A1KDM4EHPGD | |
| Questiomycin B SCHEMBL28102191 | 0.87 | ALOX15 (0.94) | ALOX15TSHRALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10884004-B2 | Taggable fluorescent probe for calcium ion detection | THE UNIVERSITY OF TOKYO (JP) | 2021-01-05 | — | — | US | claimed |
| US-20190094248-A1 | TAGGABLE FLUORESCENT PROBE FOR CALCIUM ION DETECTION | THE UNIVERSITY OF TOKYO (JP) | 2019-03-28 | — | — | US | claimed |
| US-20100056483-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF BONE LOSS | OHIO UNIVERSITY (US) | 2010-03-04 | — | — | US | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| US-10884004-B2 | Taggable fluorescent probe for calcium ion detection | THE UNIVERSITY OF TOKYO (JP) | 2021-01-05 | — | — | US | disclosed |
| US-20190094248-A1 | TAGGABLE FLUORESCENT PROBE FOR CALCIUM ION DETECTION | THE UNIVERSITY OF TOKYO (JP) | 2019-03-28 | — | — | US | disclosed |
| CN-104829593-B | A kind of organic compound and its application for being used to detect metal ion in solution content | 苏州福来兹检测科技有限公司 | 2017-08-25 | — | — | CN | disclosed |
| US-20170038398-A1 | LONG WAVELENGTH FLUOROGENIC INTRACELLULAR ION INDICATORS THAT ARE WELL RETAINED IN THE CYTOSOL | Life Technologies Corporation | 2017-02-09 | — | — | US | disclosed |
| WO-2016179217-A1 | METAL ION CHELATION FOR ENHANCING THE EFFECT OF TISSUE PLASMINOGEN ACTIVATOR (TPA) IN THROMOBOLYSIS | OHIO UNIVERSITY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-9341631-B2 | Long wavelength fluorogenic intracellular ion indicators that are well retained in the cytosol | Life Technologies Corporation (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140363839-A1 | LONG WAVELENGTH FLUOROGENIC INTRACELLULAR ION INDICATORS THAT ARE WELL RETAINED IN THE CYTOSOL | Life Technologies Corporation (US) | 2014-12-11 | — | — | US | disclosed |
| US-20130096300-A1 | LONG WAVELENGTH FLUOROGENIC INTRACELLULAR ION INDICATORS THAT ARE WELL RETAINED IN THE CYTOSOL | Life Technologies Corporation (US) | 2013-04-18 | — | — | US | disclosed |
| EP-0740528-B1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX THERAPEUTICS INC (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020031834-A1 | Fluorescent magnesium indicators | THE GOVERNMENT OF THE UNITED STATES | 2002-03-14 | — | — | US | disclosed |
| US-5773227-A | CHELATE COMPOUNDS, FLUORESCENT INDICATOR AND TARGET PEPTIDES | MOLECULAR PROBES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0740528-A4 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5733572-A | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles | IMARX PHARMACEUTICAL CORP. (US) | 1998-03-31 | — | — | US | disclosed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | disclosed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096300-A1 | LONG WAVELENGTH FLUOROGENIC INTRACELLULAR ION INDICATORS THAT ARE WELL RETAINED IN THE CYTOSOL | CHERP, MCU, GLB1 | ALOX15 2081/4885TSHR 4001/4885ALDH1A1 3508/4885 |
| US-20190094248-A1 | TAGGABLE FLUORESCENT PROBE FOR CALCIUM ION DETECTION | CACNA1G, CACNA1F, CACNA1I | ALOX15 1693/4885TSHR 3717/4885ALDH1A1 3172/4885 |
| US-10884004-B2 | Taggable fluorescent probe for calcium ion detection | CACNA1G, CACNA1F, CACNA1I | ALOX15 1693/4885TSHR 3717/4885ALDH1A1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.